本帖最后由 老马 于 2012-1-13 21:20 编辑
% M' K B6 s; [7 I3 V% G2 i9 `' Z4 X4 X9 }
爱必妥和阿瓦斯丁的比较
+ r! c6 I. k9 @, [' z7 `' x$ q1 A
2 r8 D- R! D8 c7 r7 k. E9 Hhttp://cancergrace.org/lung/2008/08/30/bms099-os-neg/7 O- H9 b k# P$ D( h8 H# q' L
+ j: q8 C3 T* f. t- Y. ]9 V
; R+ k; w. B3 f( G* I/ e
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/5 p' A& W4 t/ j# x; f3 _% d Y
==================================================
. a4 z" s% z. @( KOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
; i2 x* \" X& @Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.1 A7 X7 ]+ J, d B
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (～62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
; x# C1 @4 e6 v
|
显身卡
